Fifty years ago, the first successful isolation of enzymes and the study of their reaction mechanisms challenged biochemists to investigate their biological regulation. Various models have been proposed on the basis of available catalytical, pharmacological and structural information. The "allosteric model" of Monod, Wyman and Changeux describes regulatory proteins that can adopt multiple interconvertible conformations, differently stabilized by substrates, products and allosteric effectors. These effectors target regulatory sites topographically distinct from the enzymatic reaction center. Each conformational state is characterized by a unique set of pharmacological, functional and structural properties. The oligomeric nature of the proteins which were used to construct this model allowed to describe an important phenomenon, referred to as cooperativity. It explains how the binding of a molecule to one subunit of the protein can facilitate, or conversely impede, the binding of a second molecule to a neighboring subunit. This concept has evolved and now extends to allosteric regulatory phenomena dealing with distinct effectors that bind to their own sites on a monomeric protein, such as a G-protein coupled receptor. This article focuses on G-protein-coupled receptors and aims to discuss (1) how their functional architecture meets the rules of allostery, and (2) how allosteric effectors (small molecules or cell components), with which the receptors establish stable or transient interactions, may cooperate to finely tune their pharmacological and functional properties.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1051/medsci/20122810013 | DOI Listing |
Nat Chem
January 2025
Institute of Bioengineering, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland.
Protein catalysis and allostery require the atomic-level orchestration and motion of residues and ligand, solvent and protein effector molecules. However, the ability to design protein activity through precise protein-solvent cooperative interactions has not yet been demonstrated. Here we report the design of 14 membrane receptors that catalyse G protein nucleotide exchange through diverse engineered allosteric pathways mediated by cooperative networks of intraprotein, protein-ligand and -solvent molecule interactions.
View Article and Find Full Text PDFAngew Chem Int Ed Engl
January 2025
University of Amsterdam Van 't Hoff Institute for Molecular Sciences: Universiteit van Amsterdam Van 't Hoff Institute for Molecular Sciences, HIMS, NETHERLANDS, KINGDOM OF THE.
The complexity of allosteric enzymatic regulation continues to inspire synthetic chemists seeking to emulate interconnected biological systems. In this work, a Pt2L4 cage capable of catalyzing the cyclization reaction of an alkynoic tosyl amide is orthogonally coupled to a diacid-catalyzed carbodiimide-hydration cycle. This new Pt-catalyzed cyclization reaction is demonstrated to exhibit electronic regulation by inclusion of different guest effectors.
View Article and Find Full Text PDFJ Cell Mol Med
January 2025
Centre for Molecular Biophysics, UPR CNRS 4301, Orleans, France.
The hypoxic microenvironment is crucial for tumour cell growth and invasiveness. Tumour tissue results from adaptation to reduced oxygen availability. Hypoxia first activates pro-angiogenic signals for alleviation.
View Article and Find Full Text PDFNucleic Acids Res
January 2025
Department of Biochemistry, University of Zurich, Winterthurerstrass 190, 8057 Zurich, Switzerland.
Type III clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) systems (type III CRISPR-Cas systems) use guide RNAs to recognize RNA transcripts of foreign genetic elements, which triggers the generation of cyclic oligoadenylate (cOA) second messengers by the Cas10 subunit of the type III effector complex. In turn, cOAs bind and activate ancillary effector proteins to reinforce the host immune response. Type III systems utilize distinct cOAs, including cyclic tri- (cA3), tetra- (cA4) and hexa-adenylates (cA6).
View Article and Find Full Text PDFBiochem Biophys Rep
March 2025
Genis hf, Reykjavik, Iceland.
The chitinase-like protein YKL-40 (CHI3L1) has been implicated in the pathophysiology of inflammation and cancer. Recent studies highlight the growing interest in targeting and blocking the activity of YKL-40 to treat cancer. Some of those targeting-strategies have been developed to directly block the heparin-affinity of YKL-40 with promising results.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!